ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2200

Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis

Sheue-Fang Shih1, Carl Brown 1, Tien-Tzu Tai 1 and Wing Chuang 1, 1Taiwan Liposome Company, Ltd., Taipei, Taiwan (Republic of China)

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: dexamethasone, magnetic resonance imaging (MRI) and cartilage, Osteoarthritis

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Tuesday, November 12, 2019

Session Title: Osteoarthritis – Clinical Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The most commonly used intra-articular (IA) corticosteroid for osteoarthritis (OA) is triamcinolone acetonide (TA), but its potential chondrotoxicity restricts injection frequency to 3-4 injections per year. TLC599 is a liposomal formulation of dexamethasone sodium phosphate (DSP) designed for intra-articular injection in the treatment of knee osteoarthritis (OA). Based on a Phase 2a multi-center, randomized, double-blind, placebo-controlled clinical trial (ClinicalTrials.gov ID: NCT03005873), TLC599 has demonstrated durable pain relief and improved function over 24 weeks in patients with knee OA pain. Also, TLC599 possess the potential to protect articular cartilage from damage, making it potentially a beneficial therapy for OA with less risk of chondrotoxicity. To evaluate the effect of TLC599 on knee cartilage, magnetic resonance imaging (MRI) was utilized in this trial.

Methods: In the current Phase 2a study, subjects were eligible if they met the American College of Rheumatology Criteria for knee OA, with Grade 2 to 3 Kellgren-Lawrence severity. A total of 75 patients were randomized to receive 1 of the 3 regimens in the index knee in 1:1:1 ratio (TLC599 with 12 mg DSP and 100 μmol phospholipid (PL); TLC599 18 mg DSP with 150 μmol PL; or normal saline placebo). Patients were followed 24 weeks post injection. MRI was conducted on both knees before dosing and at the end of study, and cartilage was evaluated by a blinded radiologist at each center using the MRI Osteoarthritis Knee Score (MOAKS) instrument, with 14 articular subregions individually evaluated with 2 categorical scores, indicating the size of cartilage damage (surface area loss) and depth of cartilage damage (full thickness loss).

Results: Index knees were compared with non-index knees by number of sub-regions with worsening from baseline to the end of 24 weeks (≥ 2 sub-regions worsening representing significant worsening), regardless of the individual sub-region severity. Table 1 shows the MOAKS score pattern for placebo group index and non-index knees, representing the natural course of the disease, and the TLC599 group knees. For the placebo group, the index knee displayed similar or more significant cartilage damage (≥ 2 sub-regions with worsening) than the non-index knee, for both joint cartilage surface area and thickness. However, both TLC599 patient groups displayed lower proportions of significant cartilage damage in the index knee than the non-index knee. Figure 1 shows that the pattern of knee joint cartilage damage change between treated groups was reflected by the difference between the proportions of subjects displaying ≥2 worsening cartilage sub-regions in index vs. non-index knee. These findings suggest there may be protection from cartilage degeneration by TLC599 IA injection.

Conclusion: The exploratory MRI evaluation of knee cartilage using semi-quantitative MOAKS indicated that, comparing index to non-index knees, patients treated with TLC599 IA injection displayed relatively less cartilage loss in the treated knee than placebo patients, suggesting a lack of cartilage damage or potentially a chondroprotective effect.

Table 1. Comparison of significant cartilage damage by MOAKS between placebo- and TLC599-treated patients

Figure 1. Difference in proportions with cartilage deterioration between index knee and non-index knee


Disclosure: S. Shih, Taiwan Liposome Company, Ltd., 1, 3; C. Brown, Taiwan Liposome Company, Ltd., 1, 3; T. Tai, Taiwan Liposome Company, Ltd., 1, 3; W. Chuang, Taiwan Liposome Company, Ltd., 1, 3.

To cite this abstract in AMA style:

Shih S, Brown C, Tai T, Chuang W. Magnetic Resonance Imaging of Knee Joint Protection Following an Intra-Articular Injection of Lipid-Based Dexamethasone Sodium Phosphate Sustained Release Formulation on Subjects with Knee Osteoarthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/magnetic-resonance-imaging-of-knee-joint-protection-following-an-intra-articular-injection-of-lipid-based-dexamethasone-sodium-phosphate-sustained-release-formulation-on-subjects-with-knee-osteoarthri/. Accessed January 28, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/magnetic-resonance-imaging-of-knee-joint-protection-following-an-intra-articular-injection-of-lipid-based-dexamethasone-sodium-phosphate-sustained-release-formulation-on-subjects-with-knee-osteoarthri/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.